BACKGROUND: The hippocampus (HC) is smaller in patients with recurrent major depressive disorder (MDD), but few longitudinal studies have examined whether volume is associated with clinically meaningful outcomes such as response to treatment. METHODS: We compared regional (head and body/tail) HC volumes in 46 patients with MDD, 14 of whom remitted after 8 weeks of first treatment to HC volumes of 32 patients who were not in remission after 8 weeks. RESULTS: Patients who remitted had larger pretreatment hippocampal body/tail volumes bilaterally compared with those who were not in remission at 8 weeks. This difference was not apparent in either the right or left hippocampal head. CONCLUSIONS: These findings extend a small number of previous reports, suggesting that regional brain volumes might be associated with rate and extent of clinical response to antidepressant medication.
BACKGROUND: The hippocampus (HC) is smaller in patients with recurrent major depressive disorder (MDD), but few longitudinal studies have examined whether volume is associated with clinically meaningful outcomes such as response to treatment. METHODS: We compared regional (head and body/tail) HC volumes in 46 patients with MDD, 14 of whom remitted after 8 weeks of first treatment to HC volumes of 32 patients who were not in remission after 8 weeks. RESULTS:Patients who remitted had larger pretreatment hippocampal body/tail volumes bilaterally compared with those who were not in remission at 8 weeks. This difference was not apparent in either the right or left hippocampal head. CONCLUSIONS: These findings extend a small number of previous reports, suggesting that regional brain volumes might be associated with rate and extent of clinical response to antidepressant medication.
Authors: M I Geerlings; S Sigurdsson; G Eiriksdottir; M E Garcia; T B Harris; T Sigurdsson; V Gudnason; L J Launer Journal: Psychol Med Date: 2012-05-30 Impact factor: 7.723
Authors: Nikita Nogovitsyn; Meghan Muller; Roberto Souza; Stefanie Hassel; Stephen R Arnott; Andrew D Davis; Geoffrey B Hall; Jacqueline K Harris; Mojdeh Zamyadi; Paul D Metzak; Zahinoor Ismail; Jonathan Downar; Sagar V Parikh; Claudio N Soares; Jean M Addington; Roumen Milev; Kate L Harkness; Benicio N Frey; Raymond W Lam; Stephen C Strother; Susan Rotzinger; Sidney H Kennedy; Glenda M MacQueen Journal: Neuropsychopharmacology Date: 2019-10-14 Impact factor: 7.853
Authors: Erica L Tatham; Geoff B C Hall; Darren Clark; Jane Foster; Rajamannar Ramasubbu Journal: Eur Arch Psychiatry Clin Neurosci Date: 2016-06-08 Impact factor: 5.270
Authors: Elizabeth A Bartlett; Christine DeLorenzo; Priya Sharma; Jie Yang; Mengru Zhang; Eva Petkova; Myrna Weissman; Patrick J McGrath; Maurizio Fava; R Todd Ogden; Benji T Kurian; Ashley Malchow; Crystal M Cooper; Joseph M Trombello; Melvin McInnis; Phillip Adams; Maria A Oquendo; Diego A Pizzagalli; Madhukar Trivedi; Ramin V Parsey Journal: Neuropsychopharmacology Date: 2018-06-19 Impact factor: 7.853
Authors: Carrie E Bearden; Paul M Thompson; Christina Avedissian; Andrea D Klunder; Mark Nicoletti; Nicole Dierschke; Paolo Brambilla; Jair C Soares Journal: ASN Neuro Date: 2009-11-10 Impact factor: 4.146
Authors: Andrew F Leuchter; Ian A Cook; Steven P Hamilton; Katherine L Narr; Arthur Toga; Aimee M Hunter; Kym Faull; Julian Whitelegge; Anne M Andrews; Joseph Loo; Baldwin Way; Stanley F Nelson; Steven Horvath; Barry D Lebowitz Journal: Curr Psychiatry Rep Date: 2010-12 Impact factor: 5.285
Authors: Paul M Macey; Christopher A Richard; Rajesh Kumar; Mary A Woo; Jennifer A Ogren; Christina Avedissian; Paul M Thompson; Ronald M Harper Journal: PLoS One Date: 2009-07-30 Impact factor: 3.240
Authors: Preethi Premkumar; Dominic Fannon; Elizabeth Kuipers; Emmanuelle R Peters; Ananatha P P Anilkumar; Andrew Simmons; Veena Kumari Journal: Schizophr Res Date: 2009-09-05 Impact factor: 4.939